Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data - PubMed (original) (raw)

Review

doi: 10.1136/bmj.i6583.

David A Jolliffe 3, Richard L Hooper 3, Lauren Greenberg 3, John F Aloia 4, Peter Bergman 5, Gal Dubnov-Raz 6, Susanna Esposito 7, Davaasambuu Ganmaa 8, Adit A Ginde 9, Emma C Goodall 10, Cameron C Grant 11, Christopher J Griffiths 3 2 12, Wim Janssens 13, Ilkka Laaksi 14, Semira Manaseki-Holland 15, David Mauger 16, David R Murdoch 17, Rachel Neale 18, Judy R Rees 19, Steve Simpson Jr 20, Iwona Stelmach 21, Geeta Trilok Kumar 22, Mitsuyoshi Urashima 23, Carlos A Camargo Jr 24

Affiliations

Review

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Adrian R Martineau et al. BMJ. 2017.

Abstract

Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect.Design Systematic review and meta-analysis of individual participant data (IPD) from randomised controlled trials.Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and the International Standard Randomised Controlled Trials Number registry from inception to December 2015.Eligibility criteria for study selection Randomised, double blind, placebo controlled trials of supplementation with vitamin D3 or vitamin D2 of any duration were eligible for inclusion if they had been approved by a research ethics committee and if data on incidence of acute respiratory tract infection were collected prospectively and prespecified as an efficacy outcome.Results 25 eligible randomised controlled trials (total 11 321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10 933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio 0.88, 95% confidence interval 0.81 to 0.96; P for heterogeneity <0.001). In subgroup analysis, protective effects were seen in those receiving daily or weekly vitamin D without additional bolus doses (adjusted odds ratio 0.81, 0.72 to 0.91) but not in those receiving one or more bolus doses (adjusted odds ratio 0.97, 0.86 to 1.10; P for interaction=0.05). Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (adjusted odds ratio 0.30, 0.17 to 0.53) than in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (adjusted odds ratio 0.75, 0.60 to 0.95; P for interaction=0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted odds ratio 0.98, 0.80 to 1.20, P=0.83). The body of evidence contributing to these analyses was assessed as being of high quality.Conclusions Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.Systematic review registration PROSPERO CRD42014013953.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare financial support for this work from the National Institute for Health Research under its Health Technology Assessment programme. No author has had any financial relationship with any organisations that might have an interest in the submitted work in the previous three years. No author has had any other relationship, or undertaken any activity, that could appear to have influenced the submitted work.

Figures

None

Fig 1 Flow of study selection. IPD=individual participant data

None

Fig 2 Two step individual participant data meta-analysis: proportion of participants experiencing at least one acute respiratory tract infection (ARTI). Data from trial by Simpson et al

were not included in this two step meta-analysis, as an estimate for the effect of the intervention in the study could not be obtained in the regression model owing to small sample size

Comment in

Similar articles

Cited by

References

    1. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009;302:758-66. 10.1001/jama.2009.1163 pmid:19690308. - DOI - PMC - PubMed
    1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71. 10.1016/S0140-6736(14)61682-2 pmid:25530442. - DOI - PMC - PubMed
    1. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006;134:1129-40. 10.1017/S0950268806007175 pmid:16959053. - DOI - PMC - PubMed
    1. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol 2013;136:321-9. 10.1016/j.jsbmb.2012.11.017 pmid:23220552. - DOI - PubMed
    1. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008;181:7090-9. 10.4049/jimmunol.181.10.7090 pmid:18981129. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources